Investigating how a specific protein variant affects cancer and DNA damage
Mdm2 Alternative Splicing in DNA Damage and Cancer
This study is looking at a special version of a protein called MDM2 that might play a role in cancer and how our bodies respond to DNA damage, with the hope of finding new treatment options for patients dealing with cancers linked to this protein.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Research Inst Nationwide Children's Hosp NIH-funded |
| Lab location | 1 site (Columbus, United States) |
| Project ID | NIH-10977409 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of an alternative form of the MDM2 protein in cancer and DNA damage response. It examines how this protein variant, MDM2-ALT1, is produced in various cancers and how it can influence the function of the tumor suppressor protein p53. The study aims to identify the mechanisms behind the generation of MDM2-ALT1 and explore potential therapeutic strategies using splice-switching oligonucleotides to target this protein variant. Patients may benefit from insights that could lead to new treatments for cancers associated with this protein.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cancers such as pediatric high-grade gliomas, astrocytomas, rhabdomyosarcomas, lymphomas, and breast cancer.
Not a fit: Patients with cancers not associated with MDM2-ALT1 or those without a diagnosis of cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new targeted therapies for various cancers by manipulating the expression of MDM2-ALT1.
How similar studies have performed: Other research has shown promising results in targeting alternative splicing in cancer, suggesting that this approach may be effective.
Where this research is happening
Columbus, United States
- Research Inst Nationwide Children's Hosp — Columbus, United States (Active)
Researchers
- Principal investigator: Chandler, Dawn S — Research Inst Nationwide Children's Hosp
- Study coordinator: Chandler, Dawn S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.